Form 4: Sutro Biopharma Director Acquires Stock Options

Sutro Biopharma Director Joseph M. Lobacki acquired 10,000 stock options with an exercise price of $26.09, vesting over time with full vesting by June 5, 2027.

Summary

• Joseph M. Lobacki, a Director at Sutro Biopharma, Inc., was granted 10,000 stock options on June 5, 2026.
• The options have an exercise price of $26.09 per share.
• Vesting occurs monthly at a rate of 8.33% of the total award, with the first tranche vesting on July 5, 2026.
• The award will be fully vested and exercisable by June 5, 2027, or earlier if it coincides with the issuer's 2027 annual stockholders meeting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard compensation practice for a director, indicating continued engagement and alignment with company performance.

Positives

• Director acquisition of stock options indicates confidence in the company's future prospects.
• The stock options provide a potential incentive for the director to drive company growth and shareholder value.
• The vesting schedule aligns the director's incentives with the company's long-term performance.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the stock options is subject to market fluctuations and the company's stock performance.
• The vesting schedule implies that the full benefit of the options is contingent on continued service and company performance.

Future Outlook

The stock options granted to the director are subject to vesting over time, with full exercisability expected by June 5, 2027, or earlier if aligned with the 2027 annual stockholders meeting, suggesting a long-term incentive structure.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biopharmaceutical industry as a means to attract, retain, and incentivize key leadership, aligning their interests with long-term shareholder value creation.

Related Party Transactions

• Grant of 10,000 stock options to Director Joseph M. Lobacki.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as a sign of commitment and alignment with shareholder interests.
• Employees: Standard compensation practice that does not directly impact employees.
• Management: Reinforces standard executive compensation practices.

Next Steps

• Continued service by Joseph M. Lobacki as Director.
• Monthly vesting of stock options commencing July 5, 2026.
• Full vesting and exercisability of stock options by June 5, 2027, or the 2027 annual stockholders meeting.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Stock Options, Insider Trading, Director Compensation, Beneficial Ownership, SEC Filing